News
PDSB
1.050
-6.25%
-0.070
Weekly Report: what happened at PDSB last week (0608-0612)?
Weekly Report · 2h ago
Weekly Report: what happened at PDSB last week (0601-0605)?
Weekly Report · 06/08 09:06
PDS Biotechnology Regains Nasdaq Compliance, Listing Risk Removed
TipRanks · 06/02 19:57
PDS Biotech regains Nasdaq compliance after shares close above $1 bid threshold
PUBT · 06/02 19:35
Weekly Report: what happened at PDSB last week (0525-0529)?
Weekly Report · 06/01 09:06
Weekly Report: what happened at PDSB last week (0518-0522)?
Weekly Report · 05/25 09:07
PDS Biotechnology Streamlines Trials in Pivotal Earnings Call
TipRanks · 05/20 05:25
Weekly Report: what happened at PDSB last week (0511-0515)?
Weekly Report · 05/18 09:07
PDS Biotechnology Earnings Call Highlights Trial Acceleration
TipRanks · 05/14 00:52
Analysts’ Top Healthcare Picks: Verastem (VSTM), PDS Biotechnology (PDSB)
TipRanks · 05/13 15:10
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
Seeking Alpha · 05/13 14:11
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
Benzinga · 05/13 12:26
Earnings Scheduled For May 13, 2026
Benzinga · 05/13 11:11
PDS Biotechnology GAAP EPS of -$0.13
Seeking Alpha · 05/13 11:10
PDS Biotech Q1 FY26 net loss narrows to $7.3 million; R&D expenses drop to $3.5 million
PUBT · 05/13 11:09
PDS Biotechnology Q1 net loss narrows
Reuters · 05/13 11:08
*PDS Biotechnology 1Q Research and Development Expenses $3.5M >PDSB
Dow Jones · 05/13 11:05
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate
Benzinga · 05/13 11:01
BRIEF-PDS Biotechnology Q1 EPS USD -0.13
Reuters · 05/13 11:00
Press Release: PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Dow Jones · 05/13 11:00
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.